Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652131 | 1.00 | HTT (0.32) | HTTKMT5ADPP4HSD11B1LMNA | |
| SCHEMBL3364565 | 1.00 | HTT (0.32) | HTTKMT5ADPP4HSD11B1LMNA | |
| SCHEMBL15946734 | 0.86 | CHRNB2 (0.43) | HTTKMT5ADPP4HSD11B1 | |
| SCHEMBL21707130 | 0.81 | TEAD1 (0.46) | — | |
| SCHEMBL9790975 | 0.77 | KMT5A (0.42) | KMT5A | |
| SCHEMBL21707126 | 0.74 | TEAD1 (0.47) | — | |
| SCHEMBL4798583 | 0.74 | USP30 (0.38) | DPP4HSD11B1USP30 | |
| SCHEMBL4887983 | 0.74 | CHRNB2 (0.36) | DPP4HSD11B1USP30 | |
| SCHEMBL3786744 | 0.72 | CHRNB2 (0.33) | — | |
| SCHEMBL2413966 | 0.72 | HCRTR1 (0.45) | KMT5ADPP4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| US-9777020-B2 | Furo-3-carboxamide derivatives and methods of use | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. | 2015-07-30 | — | — | US | disclosed |
| US-8399468-B2 | Octahydro-pyrrolo[3,4-B]pyrrole derivatives | ABBOTT LABORATORIES (US) | 2013-03-19 | — | — | US | disclosed |
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-8026240-B2 | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides | ABBOTT LABORATORIES (US) | 2011-09-27 | — | — | US | disclosed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-7728031-B2 | Octahydro-pyrrolo[3,4-b]pyrrole derivatives | ABBOTT LABORATORIES (US) | 2010-06-01 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070232612-A1 | Octahydro-pyrrolo[3,4-b]pyrrole Derivatives | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232612-A1 | Octahydro-pyrrolo[3,4-b]pyrrole Derivatives | HRH4, HRH2, TAC3 | HTT 853/4885KMT5A 3642/4885DPP4 1789/4885 |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | NTRK2, MUSK, NTRK3 | HTT 4252/4885KMT5A 3467/4885DPP4 2063/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | HTT 3007/4885KMT5A 2447/4885DPP4 3632/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | HTT 1114/4885KMT5A 1294/4885DPP4 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.